Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hunan Province Tumor Hospital
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
1. ≥18，advanced non-small cell lung cancer confirmed by histopathology, and have received K-drug mono-therapy in the past, the return visit information is complete, with traceable information such as tumor imaging examinations before and after treatment, and the curative effect can be judged;
2. Able to provide FFPE samples with a storage life of 4 years: 6 slices of continuous slices with a thickness of 3-5μm
You may not be if
1. Pathological evaluation of the tissue sample has too few tumor cells (total number of tumor cells \<100);
2. K-drug mono-therapy is neoadjuvant therapy or adjuvant therapy;
3. Other situations that the investigator thinks are not suitable for participating in this clinical study
Clareo Health | Consistency of PD-L1 Detecting Method Between E1L3N and 22C3 Monoclonal Antibodies in NSCLC Patients
